Cnp prodrugs with large carrier moieties

Abstract

The present invention relates to a CNP prodrug or a pharmaceutically acceptable salt thereof comprising a CNP moiety -D; and a carrier moiety —Z that is conjugated through a moiety -L2- to a reversible prodrug linker moiety -L1-, which reversible prodrug linker moiety -L1- is covalently and reversibly conjugated to -D; wherein -L2- is a chemical bond or a spacer; and —Z is a polymer having a molecular weight of at least 10 kDa. It further relates to pharmaceutical compositions comprising the CNP prodrug or a pharmaceutically acceptable salt thereof, their use as a medicament and to methods of treatment.

1 . A CNP prodrug or a pharmaceutically acceptable salt thereof comprising
 a CNP moiety -D; and   a carrier moiety —Z that is conjugated through a moiety -L 2 - to a reversible prodrug linker moiety -L′-, which reversible prodrug linker moiety -L 1 - is covalently and reversibly conjugated to -D;   wherein   L 2 - is a chemical bond or a spacer; and   —Z is a polymer having a molecular weight of at least 10 kDa.   
     
     
         2 . The CNP prodrug or a pharmaceutically acceptable salt thereof of  claim 1 , wherein —Z is a linear, branched, multi-arm or dendritic polymeric moiety. 
     
     
         3 . The CNP prodrug or a pharmaceutically acceptable salt thereof of  claim 1 , wherein —Z is a branched polymer. 
     
     
         4 . The CNP prodrug or a pharmaceutically acceptable salt thereof of any one of  claim 1 , wherein —Z is a branched polymer having one, two, three, four, five or six branching points. 
     
     
         5 . The CNP prodrug or a pharmaceutically acceptable salt thereof of  claim 4 , wherein each branching points is independently selected from the group consisting of —N<, —CH< and >C<. 
     
     
         6 . The CNP prodrug or a pharmaceutically acceptable salt thereof of  claim 1 , wherein —Z has a molecular weight ranging from and including 10 kDa to 80 kDa. 
     
     
         7 . The CNP prodrug or a pharmaceutically acceptable salt thereof of  claim 1 , wherein —Z comprises a moiety 
       
         
           
           
               
               
           
         
       
     
     
         8 . The CNP prodrug or a pharmaceutically acceptable salt thereof of  claim 1 , wherein —Z comprises a moiety of formula (a) 
       
         
           
           
               
               
           
         
         wherein 
         the dashed line indicates attachment to -L 2 - or to the remainder of —Z; 
         BP a  is a branching point selected from the group consisting of —N<, —CR< and >C<; 
         —R is selected from the group consisting of —H and C 1-6  alkyl; 
         a is 0 if BP a  is —N< or —CR< and a is 1 if BP a  is >C<; 
         —S a —, —S a′ —, —S a″ — and S a′″ — are independently of each other a chemical bond or are selected from the group consisting of C 1-50  alkyl, C 2-50  alkenyl, and C 2-50  alkynyl; wherein C 1-50  alkyl, C 2-50  alkenyl, and C 2-50  alkynyl are optionally substituted with one or more —R 1 , which are the same or different and wherein C 1-50  alkyl, C 2-50  alkenyl, and C 2-50  alkynyl are optionally interrupted by one or more groups selected from the group consisting of -T-, —C(O)O—, —O—, —C(O)—, —C(O)N(R 2 )—, —S(O) 2 N(R 2 )—, —S(O)N(R 2 )—, —S(O) 2 —, —S(O)—, —N(R 2 )S(O) 2 N(R 2a )—, —S—, —N(R 2 )—, —OC(OR 2 )(R 2a )—, —N(R 2 )C(O)N(R 2a )—, and —OC(O)N(R 2 )—; 
         each -T- is independently selected from the group consisting of phenyl, naphthyl, indenyl, indanyl, tetralinyl, C 3-10  cycloalkyl, 3- to 10-membered heterocyclyl, 8- to 11-membered heterobicyclyl, 8- to 30-membered carbopolycyclyl, and 8- to 30-membered heteropolycyclyl; wherein each -T- is independently optionally substituted with one or more —R 1 , which are the same or different; 
         each —R 1  is independently selected from the group consisting of halogen, —CN, oxo (═O), —COOR 3 , —OR 3 , —C(O)R 3 , —C(O)N(R 3 R 3a ), —S(O) 2 N(R 3 R 3a ), —S(O)N(R 3 R 3a ), —S(O) 2 R 3 , —S(O)R 3 , —N(R 3 )S(O) 2 N(R 3a R 3b ), —SR 3 , —N(R 3 R 3a ), —NO 2 , OC(O)R 3 , —N(R 3 )C(O)R 3a , —N(R 3 )S(O) 2 R 3a , N(R 3 )S(O)R 3a , —N(R 3 )C(O)OR 3a , —N(R 3 )C(O)N(R 3a R 3b ), OC(O)N(R 3 R 3a ), and C 1-6  alkyl; wherein C 1-6  alkyl is optionally substituted with one or more halogen, which are the same or different; 
         each —R 2 , —R 2a  —R 3 , —R 3a  and —R 3b  is independently selected from the group consisting of —H, and C 1-6  alkyl, wherein C 1-6  alkyl is optionally substituted with one or more halogen, which are the same or different; and 
         —P a′ , —P a″  and —P a′″  arc independently a polymeric moiety. 
       
     
     
         9 . The CNP prodrug or a pharmaceutically acceptable salt thereof of  claim 1 , wherein —Z is of formula (d) 
       
         
           
           
               
               
           
         
         wherein 
         the dashed line indicates attachment to -L 2 -; 
         —Z b — is selected from the group consisting of C 1-50  alkyl, C 2-50  alkenyl, and C 2-50  alkynyl; wherein C 1-50  alkyl, C 2-50  alkenyl, and C 2-50  alkynyl are optionally substituted with one or more —R 1 , which are the same or different and wherein C 1-50  alkyl, C 2-50  alkenyl, and C 2-50  alkynyl are optionally interrupted by one or more groups selected from the group consisting of -T-, —C(O)O—, —O—, —C(O)—, —C(O)N(R 2 )—, —S(O) 2 N(R 2 )—, —S(O)N(R 2 )—, —S(O) 2 — —S(O)—, —N(R 2 )S(O) 2 N(R 2a )—, —S—, —N(R 2 )—, —OC(OR 2 )(R 2a )N(R 2 )C(O)N(R 2a )—, and —OC(O)N(R 2 )—; 
         each -T- is independently selected from the group consisting of phenyl, naphthyl, indenyl, indanyl, tetralinyl, C 3-10  cycloalkyl, 3- to 10-membered heterocyclyl, 8- to 11-membered heterobicyclyl, 8- to 30-membered carbopolycyclyl, and 8- to 30-membered heteropolycyclyl; wherein each -T- is independently optionally substituted with one or more —R 1 , which are the same or different; 
         each —R 1  is independently selected from the group consisting of halogen, —CN, oxo (═O), —COOR 3 , —OR 3 , —C(O)R 3 , —C(O)N(R 3 R 3a ), —S(O) 2 N(R 3 R 3a ), —S(O)N(R 3 R 3a ), —S(O) 2 R 3 , —S(O)R 3 , —N(R 3 )S(O) 2 N(R 3a R 3b ), —SR 3 , —N(R 3 R 3a ), —NO 2 , —OC(O)R 3 , —N(R 3 )C(O)R 3a , —N(R 3 )S(O) 2 R 3a , —N(R 3 )S(O)R 3a , —N(R 3 )C(O)OR 3a , —N(R 3 )C(O)N(R 3a R 3b ), —OC(O)N(R 3 R 3a ), and C 1-6  alkyl; wherein C 1-6  alkyl is optionally substituted with one or more halogen, which are the same or different; 
         each —R 2 , —R 2a , —R 3 , —R 3a  and —R 3b  is independently selected from the group consisting of —H, and C 1-6  alkyl, wherein C 1-6  alkyl is optionally substituted with one or more halogen, which are the same or different; 
         and 
         —Z a  is 
         —Z a  is 
       
       
         
           
           
               
               
           
         
         wherein 
         BP a , —S a —, —S a′ —, —S a″ , —S a′″ —, —P a′ , —P a″ , —P a′″  and a are used as defined in  claim 5 . 
       
     
     
         10 . The CNP prodrug or a pharmaceutically acceptable salt thereof of  claim 1 , wherein -D has the sequence of SEQ ID NO:24, SEQ ID NO:25 or SEQ ID NO:30. 
     
     
         11 . The CNP prodrug or a pharmaceutically acceptable salt thereof of  claim 1 , wherein -L 1 - is conjugated to the side chain of an amino acid residue of the ring moiety of -D or to the backbone of the ring moiety of -D. 
     
     
         12 . A pharmaceutical composition comprising at least one CNP prodrug or a pharmaceutically acceptable salt thereof of  claim 1  and at least one excipient. 
     
     
         13 - 17 . (canceled) 
     
     
         18 . A method of treating, controlling, delaying or preventing in a mammalian patient in need of the treatment of one or more diseases which can be treated with CNP, comprising the step of administering to said patient in need thereof a therapeutically effective amount of the CNP prodrug or a pharmaceutically acceptable salt thereof of  claim 1 . 
     
     
         19 . The method of  claim 8 , wherein the one or more diseases which can be treated with CNP is selected from the group consisting of achondroplasia, hypochondroplasia, short stature, dwarfism, osteochondrodysplasias, thanatophoric dysplasia, osteogenesis imperfecta, achondrogenesis, chondrodysplasia punctata, homozygous achondroplasia, camptomelic dysplasia, congenital lethal hypophosphatasia, perinatal lethal type of osteogenesis imperfecta, short-rib polydactyly syndromes, rhizomelic type of chondrodysplasia punctata, Jansen-type metaphyseal dysplasia, spondyloepiphyseal dysplasia congenita, atelosteogenesis, diastrophic dysplasia, congenital short femur, Langer-type mesomelic dysplasia, Nievergelt-type mesomelic dysplasia, Robinow syndrome, Reinhardt syndrome, acrodysostosis, peripheral dysostosis, Kniest dysplasia, fibrochondrogenesis, Roberts syndrome, acromesomelic dysplasia, micromelia, Morquio syndrome, Kniest syndrome, metatrophic dysplasia, spondyloepimetaphyseal dysplasia, neurofibromatosis, Legius syndrome, LEOPARD syndrome, Noonan syndrome, hereditary gingival fibromatosis, neurofibromatosis type 1, Legius syndrome, cardiofaciocutaneous syndrome, Costello syndrome, SHOX deficiency, idiopathic short stature, growth hormone deficiency, osteoarthritis, cleidocranial dysostosis, craniosynostosis (e.g., Muenke syndrome, Crouzon syndrome, Apert syndrome, Jackson-Weiss syndrome, Pfeiffer syndrome, or Crouzonodermoskeletal syndrome), dactyly, brachydactyly, camptodactyly, polydactyly, syndactyly, dyssegmental dysplasia, enchondromatosis, fibrous dysplasia, hereditary multiple exostoses, hypophosphatemi c rickets, Jaffe-Lichtenstein syndrome, Marfan syndrome, McCune-Albright syndrome, osteopetrosis and osteopoikilosis. 
     
     
         20 . The method of  claim 18 , wherein the one or more diseases which can be treated with CNP is achondroplasia.